CorMedix, Inc. to Announce Third Quarter 2015 Results on November 12, 2015
Host Conference Call at 9 am on Friday, November 13, 2015
Bedminster, New Jersey, November 4, 2015 – CorMedix Inc. (“CorMedix”) (NYSE MKT: CRMD), a specialty pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of infectious diseases in both acute and chronic care settings, today announced that a conference call will be held on Friday, November 13, 2015 at 9:00 a.m. ET to discuss the Company’s third quarter 2015 results. Randy Milby, Chief Executive Officer of CorMedix, will host the call on Friday, November 13th at 9:00 AM ET. The third quarter 2015 financial results will be released on November 12th.
In order to participate in the conference call, please call 1-877-407-8031 (U.S.), 1-201-689-8031 (outside the U.S.). The replay number is 1-877-660-6853 (U.S.), 1-201-612-7415 (outside U.S.). All participants who dial in will need to give the operator first and last name, company name and phone number and conference ID: 13624478.
Reference: CorMedix.
About CorMedix
CorMedix Inc. is a commercial-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. CorMedix's first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients including neonates, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. Please see the company's website at www.cormedix.com for additional information. Plans are in progress to expand commercial distribution into the United States, Asia, the Middle East, South America and Africa upon appropriate regulatory approval.
